Middle River, MD, United States of America

Harold W Holloway

USPTO Granted Patents = 17 (Patent Applications = 1)

CIPO Patents = 4

EPO Patents = 4 (Patent Applications = 1)

Average Co-Inventor Count = 6.8

ph-index = 9

Forward Citations = 193(Granted Patents)

Location History:

Bethesda, MD (US) (1995)
Middle River, MD (US) (2006 - 2021)

Company Filing History:

11 out of 3,435

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Raptor Pharmaceutical Corp

patents

4. 2 out of 30

National Institutes of Health (nih)

patents

5. 1 out of 1

The National Institutes of Health and Axonyx, Inc.

patent

6. 1 out of 2,202

The United States of America As Represented by the Secretary of

patents

7. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1995-2021

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10941187 - GLP-1, exendin-4, peptide analogs and uses thereof (2021-03-09),

2. 10220028 - Thio compounds (2019-03-05),

3. 9623020 - Thio compounds (2017-04-18),

4. 9084783 - Thio compounds (2015-07-21),

5. 8927725 - Thio compounds (2015-01-06),

6. 8853253 - Thalidomide analogs (2014-10-07),

7. 8853160 - GLP-1, exendin-4, peptide analogs and uses thereof (2014-10-07),

8. 8691864 - Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof (2014-04-08),

9. 8546430 - Thalidomide analogs (2013-10-01),

10. 8278272 - GLP-1, exendin-4, peptide analogs and uses thereof (2012-10-02),

11. 8258172 - Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof (2012-09-04),

12. 7973057 - Thalidomide analogs (2011-07-05),

13. 7786162 - Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof (2010-08-31),

14. 7576050 - GLP-1 exendin-4 peptide analogs and uses thereof (2009-08-18),

15. 7153882 - Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof (2006-12-26),

Title: Harold W. Holloway: Innovator in Peptide Analog Research

Introduction

Harold W. Holloway is a distinguished inventor based in Middle River, MD (US), known for his significant contributions to the field of peptide analogs. With a total of 17 patents to his name, Holloway has made remarkable advancements in the treatment of diabetes and neuroprotective therapies.

Latest Patents

Among his latest patents, Holloway has developed novel polypeptide analogs of GLP-1 and exendin-4. These polypeptides are designed to be insulinotropic and long-acting, with effects comparable to or exceeding those of equimolar amounts of GLP-1 or exendin-4. His inventions also include methods for treating diabetes by administering these polypeptides, which have demonstrated insulinotropic effects. Additionally, he has explored the use of GLP-1, exendin-4, and their analogs for neuroprotective and neurotrophic effects. Another notable patent involves thio compounds, which are characterized by a specific structure that includes various functional groups, providing a wide range of potential applications.

Career Highlights

Holloway has had a notable career, working with prestigious organizations such as the National Institutes of Health, a component of the US Department of Health & Human Services, and P2D, Inc. His work has significantly impacted the fields of diabetes treatment and neuroprotection.

Collaborations

Throughout his career, Holloway has collaborated with esteemed colleagues, including Nigel H. Greig and Arnold Brossi. These partnerships have contributed to the advancement of his research and innovations.

Conclusion

Harold W. Holloway's contributions to peptide analog research and diabetes treatment highlight his role as a leading inventor in the field. His innovative patents and collaborations continue to influence medical science and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.